Edesa Biotech Q2 net loss widens to $4.2M; progresses EB06 vitiligo Phase 2 prep

Edesa Biotech, Inc.

Net loss of $4.2M ($0.49/sh) for Q2 FY2026 vs $1.6M ($0.30/sh) in prior year.
Operating expenses rose $2.7M to $4.3M on $2.3M R&D increase for EB06 and paridiprubart prep.
Cash and cash equivalents $10.0M; working capital $8.2M as of March 31, 2026.
EB06 Phase 2 vitiligo study on track; site activations and recruitment expected mid-2026 subject to approval.
Paridiprubart Phase 3 ARDS data showed consistent treatment benefits across disease subgroups and comorbidities.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edesa Biotech, Inc. reported the three months ended March 31, 2026 results: net income a net loss of $4.2 million, or $0.49 per common share, EPS $0.49 per common share.

Period: the three months ended March 31, 2026
Net income: a net loss of $4.2 million, or $0.49 per common share
EPS: $0.49 per common share
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2026, Edesa reported a net loss of $4.2 million, or $0.49 per common share, compared to a net loss of $1.6 million, or $0.30 per common share, for the quarter ended March 31, 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edesa Biotech, Inc. reported the six months ended March 31, 2026 results: net income a net loss of $6.5 million, or $0.78 per common share, EPS $0.78 per common share.

Period: the six months ended March 31, 2026
Net income: a net loss of $6.5 million, or $0.78 per common share
EPS: $0.78 per common share
Result: reported results

Exact text from the filing

For the six months ended March 31, 2026, Edesa reported a net loss of $6.5 million, or $0.78 per common share, compared to a net loss of $3.2 million, or $0.74 per common share, for the six months ended March 31, 2025.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-003429

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.